[0321] In some embodiments, the compositions comprise at least about 1 mg, at least about 2 mg, at least about 3 mg, at least about 4 mg, at least about 5 mg, at least about 6 mg, at least about 7 mg, at least about 8 mg, at least about 9 mg, at least about 10 mg, at least about 11 mg, at least about 12 mg, at least about 13 mg, at least about 14 mg, at least about 15 mg, at least about 16 mg, at least about 17 mg, at least about 18 mg, at least about 19 mg, at least about 20 mg, at least about 21 mg, at least about 22 mg, at least about 23 mg, at least about 24 mg, at least about 25 mg, at least about 26 mg, at least about 27 mg, at least about 28 mg, at least about 29 mg, or at least about 30 mg of anti-acne ingredient (e.g., salicylic acid) per mL of composition
This commonly happens at L4-L5 or L5-S1 levels
In case of one long COVID participant the whole dataset (pgACC, dACC and muscle data) was lost due to technical issues with data transfer, and two datasets were not analysable due to technical issues during the acquisition
And so I think thats the big reason that theres so much controversy is that for whatever reason, theres some people who just dont want to look at the older trials that were very long and theyre spending all their time looking at these very short term trials